Joubert, JacquesMalan, SarelMusakwa, Lovetone2021-03-102024-10-292021-03-102024-10-292020https://hdl.handle.net/10566/16353Magister Pharmaceuticae - MPharmNeurodegenerative disorders (NDs) are a range of chronic brain disorders that includes amongst others motor function loss. Parkinson’s disease (PD) is one of the common NDs that has an insidious onset and diagnosed when dopaminergic neurons in the substantia nigra are already lost. The loss creates a deficiency of the dopamine (neurotransmitter) thereby causing neurochemical imbalance resulting in the signs and symptoms of PD. NDs overlap at multiple levels so some of the symptoms overlap as well. NDs currently have no cure yet and current drug therapies only improve the quality of life of the patients by targeting the symptoms mainly. Treatment of PD currently involves different classes of drugs and depending on the stages of the disease, some drugs can be only used as an adjunct therapy. Anti-oxidants and monoamine oxidase inhibitors (MAO-I) are part of the treatment options.enNeurodegenerative disordersParkinson’s diseasesMonoamine oxidaseOxidative stressNeuroprotectionUniversity of the Western Cape